MADUROPEPTIN, A COMPLEX OF NEW MACROMOLECULAR ANTITUMOR ANTIBIOTICS

MINORU HANADA; HIROAKI OHKUMA; TERUO YONEMOTO; KOJI TOMITA; MASARU OHBAYASHI; HIDEO KAMEI; TAKEO MIYAKI; MASATAKA KONISHI; HIROSHI KAWAGUCHI; SALVATORE FORENZA

doi:10.7164/antibiotics.44.403

MINORU HANADA, HIROAKI OHKUMA, TERUO YONEMOTO, KOJI TOMITA, MASARU OHBAYASHI, HIDEO KAMEI, TAKEO MIYAKI, MASATAKA KONISHI, HIROSHI KAWAGUCHI, SALVATORE FORENZA

Author information

MINORU HANADA
Bristol-Myers Squibb Research Institute
HIROAKI OHKUMA
Bristol-Myers Squibb Research Institute
TERUO YONEMOTO
Bristol-Myers Squibb Research Institute
KOJI TOMITA
Bristol-Myers Squibb Research Institute
MASARU OHBAYASHI
Bristol-Myers Squibb Research Institute
HIDEO KAMEI
Bristol-Myers Squibb Research Institute
TAKEO MIYAKI
Bristol-Myers Squibb Research Institute
MASATAKA KONISHI
Bristol-Myers Squibb Research Institute
HIROSHI KAWAGUCHI
Bristol-Myers Squibb Research Institute
SALVATORE FORENZA
Bristol-Myers Squibb, Pharmaceutical Research Institute

JOURNAL FREE ACCESS

1991 Volume 44 Issue 4 Pages 403-414

DOI https://doi.org/10.7164/antibiotics.44.403

Details

Abstract

Maduropeptin, a complex of new macromolecular antitumor antibiotics, is a metabolite of Actinomadura madurae H710-49. The active components maduropeptins A₁, A₂ and B are acidic chromopeptides with MW of around 22, 500 and composed of 14 types of amino acids and an unstable chromophore. The antibiotics are active in vitro against Gram-positive bacteria and highly cytotoxic to tumor cells. They produced significant prolongation of survival time of mice implanted with P388 leukemia and B16 melanoma.

Corresponding author

Register with J-STAGE for free!